EndoQuest Robotics

We’re excited to share that the PARADIGM Trial has expanded to 𝐁𝐚𝐲𝐥𝐨𝐫 𝐒𝐭. 𝐋𝐮𝐤𝐞’𝐬 𝐌𝐞𝐝𝐢𝐜𝐚𝐥 𝐂𝐞𝐧𝐭𝐞𝐫, with the site’s first procedures successfully completed by Dr. Mohamed Othman and Dr. Tara Keihanian. 🎉 Dr. Othman shared: “Using the ELS System to perform this ESD offered a glimpse into the future of true endoluminal surgery. With continued experience and following regulatory clearance, I expect robotics to become a primary modality in my practice, reshaping how I approach these procedures for appropriately selected patients.” 📌 Read more in our latest press release: https://lnkd.in/g5R6w_Tq Congratulations to Dr. Othman, Dr. Keihanian, and the Baylor team – we’re grateful for your partnership as we continue to build our foundation of clinical experience and redefine what’s possible in endoluminal surgery. Mai khalaf MD,MSc | Haydee Rochits Cueto | Vance Ratliff Jr. | CHI St. Luke's Health - Baylor St. Luke's Medical Center | Baylor College of Medicine #ESD #Gastroenterology #EndoluminalSurgery #ScarFreeSurgery #TherapeuticEndoscopy #RoboticSurgery #ClinicalTrials #MedTech #HealthcareInnovation www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not yet available for commercial sale in the United States.

The 𝐅𝐫𝐨𝐧𝐭𝐢𝐞𝐫𝐬 𝐢𝐧 𝐄𝐧𝐝𝐨𝐬𝐜𝐨𝐩𝐢𝐜 𝐒𝐮𝐫𝐠𝐞𝐫𝐲 (#FES2026) 𝐂𝐨𝐮𝐫𝐬𝐞 once again stood out as a premier, fully subscribed forum for therapeutic endoscopy and endobariatrics, highlighting the accelerating shift toward less invasive, scar-free procedures. We were honored to have Todd Wilson, MD, Chief Medical Officer at EndoQuest Robotics, participate in the 𝐄𝐧𝐝𝐨𝐥𝐮𝐦𝐢𝐧𝐚𝐥 𝐑𝐨𝐛𝐨𝐭𝐢𝐜𝐬 panel moderated by Vipul Patel, M.D., F.A.C.S., and to feature our Endoluminal Surgical (ELS) System Simulator during the hands-on session. The consistent enthusiasm and engagement from physicians remain a powerful validation of where the field is headed. Thank you to Christopher C. Thompson, MD MSc FASGE FACG AGAF, Lee Swanstrom, MD, and Michele Ryan for hosting another exceptional course. #ESD #TherapeuticEndoscopy #EndoluminalSurgery #ThirdSpaceEndoscopy #Endobariatrics #Gastroenterology #ScarFreeSurgery #RoboticSurgery www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not available for commercial sale in the United States.

Pioneering category-defining surgical robotics takes teamwork, focus, discipline, and a healthy competitive edge. Amid the long hours and uncompromising standards required to bring the world’s first endoluminal robotic surgery platform to market, we’re intentional about making time to step away together. These moments reflect the collaboration and competitive spirit at the core of our culture. We push hard, support one another and recharge with purpose. We’re growing and we’re selective. If this kind of environment excites you and you believe you have what it takes, keep an eye out for opportunities to join us. #PeoplePowered #PurposeDriven #GreatPlaceToWork #CompanyCulture #LifeAtEndoQuest #MedTech #RoboticSurgery #DoWorkThatMatters #WorkWithPurpose

We were honored to attend the inaugural 𝗦𝗖-𝗖𝗢𝗥𝗘 𝗙𝘂𝘁𝘂𝗿𝗲 𝗼𝗳 𝗘𝗻𝗱𝗼𝘀𝗰𝗼𝗽𝘆 𝗦𝘂𝗺𝗺𝗶𝘁 at Cedars-Sinai, an outstanding forum bringing together leaders shaping the next decade of gastrointestinal innovation.   Throughout the meeting, there was a clear consensus across physicians and industry experts: endoluminal surgery is poised to be the dominant innovation vector in GI over the next decade, with ESD and endoscopic full-thickness resection most frequently cited as the biggest clinical applications primed for transformation by robotics.    It was a privilege to have Todd Wilson, MD, Chief Medical Officer at EndoQuest, participate in the 𝘐𝘯𝘥𝘶𝘴𝘵𝘳𝘺 𝘗𝘦𝘳𝘴𝘱𝘦𝘤𝘵𝘪𝘷𝘦𝘴 𝘰𝘯 𝘵𝘩𝘦 𝘍𝘶𝘵𝘶𝘳𝘦 𝘰𝘧 𝘙𝘰𝘣𝘰𝘵𝘪𝘤𝘴 𝘪𝘯 𝘌𝘯𝘥𝘰𝘴𝘤𝘰𝘱𝘺 panel, expertly moderated by Omar M. Khateeb and Dennis McWilliams.   Thank you to Barham Abudayyeh MD MPH for orchestrating an outstanding meeting and for your vision in establishing SC-CORE as a defining platform to shape the future of therapeutic endoscopy.   #ESD #TherapeuticEndoscopy #EndoluminalSurgery #ThirdSpaceEndoscopy #Gastroenterology #ScarFreeSurgery #RoboticSurgery   www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not available for commercial sale in the United States.

𝗪𝗲’𝘃𝗲 𝗿𝗲𝗮𝗰𝗵𝗲𝗱 𝗮 𝗺𝗮𝗷𝗼𝗿 𝗺𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲 𝗶𝗻 𝗼𝘂𝗿 𝗽𝗶𝘃𝗼𝘁𝗮𝗹 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹. EndoQuest has received FDA approval to initiate the final stage of the 𝗣𝗔𝗥𝗔𝗗𝗜𝗚𝗠 𝗧𝗿𝗶𝗮𝗹 following a favorable interim safety review, marking an important step forward in validating a new category of surgery. 📌Read more in our latest press release: https://lnkd.in/gsi7Tbpp Thank you to our principal investigators and clinical sites for their partnership as we continue this study and work to shift complex GI procedures from traditional surgery to organ-sparing, endoluminal approaches. Eric Haas, MD | HCA Houston Healthcare Norio Fukami, MD | Mayo Clinic Scottsdale Matt Albert, MD | AdventHealth Orlando Josh Sommovilla, MD | Cleveland Clinic Hiroyuki Aihara, MD, PhD | Brigham and Women's Hospital   #ESD #Gastroenterology #ColorectalSurgery #EndoluminalSurgery #ScarFreeSurgery #TherapeuticEndoscopy #RoboticSurgery #ClinicalTrials #MedTech #HealthcareInnovation www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not yet available for commercial sale in the United States. 

We are honored to collaborate with NVIDIA as we aim to deliver the world’s first endoluminal (scar-free) robotic platform. Our next-generation system will be powered by NVIDIA’s 𝐈𝐆𝐗 𝐓𝐡𝐨𝐫 and 𝐏𝐡𝐲𝐬𝐢𝐜𝐚𝐥 𝐀𝐈 𝐬𝐨𝐟𝐭𝐰𝐚𝐫𝐞 𝐬𝐭𝐚𝐜𝐤, enabling real-time image-based intelligence, selective autonomy, and low-latency remote and collaborative robotic surgery. “𝘈𝘐 𝘢𝘯𝘥 𝘳𝘰𝘣𝘰𝘵𝘪𝘤𝘴 𝘸𝘪𝘭𝘭 𝘳𝘦𝘥𝘦𝘧𝘪𝘯𝘦 𝘵𝘩𝘦 𝘰𝘱𝘦𝘳𝘢𝘵𝘪𝘯𝘨 𝘳𝘰𝘰𝘮 𝘣𝘺 𝘦𝘯𝘩𝘢𝘯𝘤𝘪𝘯𝘨 𝘴𝘶𝘳𝘨𝘪𝘤𝘢𝘭 𝘷𝘪𝘴𝘪𝘰𝘯 𝘢𝘯𝘥 𝘱𝘳𝘦𝘤𝘪𝘴𝘪𝘰𝘯 𝘣𝘦𝘺𝘰𝘯𝘥 𝘩𝘶𝘮𝘢𝘯 𝘭𝘪𝘮𝘪𝘵𝘴. 𝘛𝘩𝘪𝘴 𝘴𝘩𝘪𝘧𝘵 𝘸𝘪𝘭𝘭 𝘦𝘯𝘢𝘣𝘭𝘦 𝘦𝘢𝘳𝘭𝘪𝘦𝘳 𝘥𝘪𝘢𝘨𝘯𝘰𝘴𝘪𝘴 𝘢𝘯𝘥 𝘩𝘪𝘨𝘩𝘭𝘺 𝘵𝘢𝘳𝘨𝘦𝘵𝘦𝘥 𝘵𝘩𝘦𝘳𝘢𝘱𝘪𝘦𝘴 𝘵𝘩𝘢𝘵 𝘮𝘪𝘯𝘪𝘮𝘪𝘻𝘦 𝘱𝘢𝘵𝘪𝘦𝘯𝘵 𝘪𝘮𝘱𝘢𝘤𝘵 𝘸𝘩𝘪𝘭𝘦 𝘮𝘢𝘹𝘪𝘮𝘪𝘻𝘪𝘯𝘨 𝘵𝘩𝘦 𝘱𝘰𝘵𝘦𝘯𝘵𝘪𝘢𝘭 𝘧𝘰𝘳 𝘤𝘶𝘳𝘦.” – Dr. Todd Wilson, Chief Medical Officer and Chairman of the International Advisory Board of EndoQuest Robotics. 📌Read more about this announcement in our latest press release: https://lnkd.in/gKwX3zha #EndoQuestRobotics #NVIDIA #NVIDIARobotics #MedTech #HealthcareInnovation #RoboticSurgery #AI #AIinHealthcare #DigitalSurgery www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not yet available for commercial sale in the United States. 

Our team in South Korea had the pleasure of hosting Mr. Hamid Jafar, founding and largest shareholder of EndoQuest Robotics. “Pioneers see no boundaries, they redraw them.” That thought stayed with us after his visit this week. Mr. Jafar is a living legend in the business world: he founded Crescent Petroleum, the Middle East’s first (and today, largest) private oil & gas enterprise, and founded the region’s first container port, laying the groundwork for the global trade hubs that exist today. He built entire industries through vision and grit. Today he continues to support our company as we build the next big thing in healthcare. Hearing him share anecdotes from his career: taking risks, defying skeptics, and pioneering new industries was a masterclass in visionary leadership. “Plan far in advance, constantly challenge assumptions, innovate tirelessly and don’t be afraid to break new ground.”   We were energized by his conviction that we are on the cusp of reshaping healthcare and improving millions of lives. Mr. Jafar’s pioneering spirit has become part of our culture at EndoQuest. We are more inspired than ever to carry that torch forward as we work to transform surgical care for millions. Crescent Enterprises | Gulftainer www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not yet available for commercial sale in the United States.

We’re energized after attending the 𝐅𝐥𝐨𝐫𝐢𝐝𝐚 𝐓𝐡𝐢𝐫𝐝 𝐒𝐩𝐚𝐜𝐞 𝐄𝐧𝐝𝐨𝐬𝐜𝐨𝐩𝐲 𝐖𝐨𝐫𝐤𝐬𝐡𝐨𝐩 in Celebration, FL, presented by the AdventHealth 𝐂𝐞𝐧𝐭𝐞𝐫 𝐟𝐨𝐫 𝐈𝐧𝐭𝐞𝐫𝐯𝐞𝐧𝐭𝐢𝐨𝐧𝐚𝐥 𝐄𝐧𝐝𝐨𝐬𝐜𝐨𝐩𝐲 (𝐂𝐈𝐄). The future of endoluminal surgery is bright ✨– evident by the impressive turnout of physicians eager to expand their endoscopic skills. We were proud to showcase the EndoQuest Endoluminal Surgical (ELS) System Simulator and give physicians the opportunity to experience the 𝐰𝐨𝐫𝐥𝐝'𝐬 𝐨𝐧𝐥𝐲 𝐟𝐮𝐥𝐥𝐲 𝐫𝐨𝐛𝐨𝐭𝐢𝐜 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐟𝐨𝐫 𝐞𝐧𝐝𝐨𝐥𝐮𝐦𝐢𝐧𝐚𝐥 𝐬𝐮𝐫𝐠𝐞𝐫𝐲. With two-handed technique of multi-jointed instruments, dynamic traction/countertraction, and independent endoscope control, the ELS System is designed to enable physicians to achieve more and overcome the limitations of current endoscopic technology. Thank you to Muhammad K Hasan M.D., Dennis Yang MD, and Peter Draganov, MD for organizing an exceptional course and for your dedication to training the next generation of physicians in cutting-edge, patient-centered procedures. #ESD #ThirdSpaceEndoscopy #Gastroenterology #EndoluminalSurgery #TherapeuticEndoscopy #ScarFreeSurgery #RoboticSurgery www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not available for commercial sale in the United States.

We’re proud to share that the full results of the randomized controlled trial from Brigham and Women's Hospital comparing robotic ESD to conventional ESD have now been published in 𝗚𝘂𝘁. 🔗 https://lnkd.in/g8fuwHXt This landmark study evaluated novice gastroenterologists with no prior ESD experience in performing robotic versus conventional ESD in a bovine explant model following brief training sessions on each technique. The investigators found that 𝗥𝗼𝗯𝗼𝘁𝗶𝗰 𝗘𝗦𝗗 with the Endoluminal Surgical (ELS) System demonstrated: 🩺 𝗜𝗺𝗽𝗿𝗼𝘃𝗲𝗱 𝘀𝗮𝗳𝗲𝘁𝘆 (0 perforations vs. 11 perforations, affecting 30% of participants in the conventional group) ⚡ 𝟮.𝟲× 𝗳𝗮𝘀𝘁𝗲𝗿 𝗿𝗲𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝘁𝗶𝗺𝗲 (32.3 min vs. 85.1 min) 🎯 𝟮.𝟱× 𝗵𝗶𝗴𝗵𝗲𝗿 𝗲𝗻 𝗯𝗹𝗼𝗰 𝗿𝗲𝘀𝗲𝗰𝘁𝗶𝗼𝗻 𝗿𝗮𝘁𝗲 (100% vs. 40%) 🧠 𝟱𝟬% 𝗹𝗲𝘀𝘀 𝗰𝗼𝗴𝗻𝗶𝘁𝗶𝘃𝗲 𝗱𝗲𝗺𝗮𝗻𝗱 (NASA-TLX 54.1 vs. 109.5) These findings highlight the enabling potential of robotic technology to accelerate the learning curve for complex endoluminal procedures such as ESD and further strengthen the growing body of pre-clinical evidence supporting the ELS System. Thank you to our collaborators at Harvard Medical School and Brigham and Women's Hospital for their partnership in advancing this important work. Christopher C. Thompson, MD MSc FASGE FACG AGAF | Hiroyuki Aihara, MD, PhD | Daniel Szvarca, MD | Trent Walradt, MD #ESD #Gastroenterology #EndoluminalSurgery #TherapeuticEndoscopy #ScarFreeSurgery #RoboticSurgery #MedTech #HealthcareInnovation www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not available for commercial sale in the United States.

We’re proud to announce our integration of 𝗡𝗩𝗜𝗗𝗜𝗔 𝗜𝗚𝗫 𝗧𝗵𝗼𝗿, a cutting-edge platform powered by NVIDIA Blackwell, into our next-generation endoluminal robotic system. This collaboration will enable real-time image processing, precise robotic control, and secure cloud intelligence – all within a unified architecture designed to scale clinically and commercially. 📢 Read the full announcement in our latest release: https://lnkd.in/gYrynU-W 🔗 Read NVIDIA’s blog post: https://lnkd.in/gjWUGyGj By harnessing NVIDIA's advanced technologies, we aim to streamline system performance and empower physicians with richer data, sharper insights, and enhanced control that can advance procedural safety and clinical outcomes. #EndoQuestRobotics #NVIDIA #NVIDIARobotics #MedTech #HealthcareInnovation #RoboticSurgery #AI #AIinHealthcare #DigitalSurgery www.endoquestrobotics.com The Endoluminal Surgical System is an investigational device, has not been cleared by the FDA, and is not yet available for commercial sale in the United States.